Perth, Australia,, February 6, 2025 / Prnewswire / – Silver biopharma (ASX: RGT) (OTCQB: RGTLF)A biopharmaceutical clinical stage company brings hope to patients with epilepsy.
For thousands of patients with refractory epilepsy – commonly known as drug resistant – search for effective treatment often resembles navigation in an endless labyrinth. These people, around 30% of the epilepsy community, live with convulsions that persist despite conventional therapies. Now, a revolutionary solution, Cannpil®, offers hope.
Developed by Biopharma Limited silver, Cannepil® is an oral mucosal solution with high CBD and low THC formulation. It is designed to reduce the frequency and severity of crises while minimizing psychoactive effects. After years of clinical development, Canepil® has waves in the United Kingdom as part of a movement to transform a severe epilepsy treatment.
This breakthrough follows GW pharmaceuticals’ $ 7.2 billion Acquisition, highlighting the potential of cannabis epilepsy treatments. The Biopharma’s Cannpil® silver is about to follow a similar trajectory, offering a new solution for drug -resistant epileptic patients worldwide.
An important step for British patients
The trip from Cannpil® to the United Kingdom was historic. In collaboration with the I am Billy Foundation – named after Billy CaldwellA young boy whose severe epilepsy launched a national conversation on medical cannabis – The first patient in the United Kingdom received Canepil® as part of the clinical consulting service specializing in NHS (rescas) epilepsy.
The inclusion of Cannpil® in the patient’s patient request system of the United Kingdom changes the situation. This route allows the doctors of the General Medical Council (GMC) The specialized register of prescribing it to patients with urgent medical needs. For families that have been struggling for years, this development is a much necessary rescue buoy.
What brings out Cannepil®?
The success of Canepil® lies in its clinical tests and its rigorous security profile. A notable Australian study confirmed that it would not alter driving performance, providing insurance to patients and families. Its deployment in Ireland In 2019, under complete government health insurance, marked the start of its international impact.
Now, with availability in the United Kingdom, Cannepil® is not only a treatment – it is a symbol of progress in the fight against epilepsy resistant to medication. Its high CBD content, known for its anti-efficiency properties, provides an effective alternative for patients who have exhausted other options.
In addition, Canepil® has undergone a rigorous clinical assessment, with studies demonstrating a very security profile, including evidence that it does not cause activities such as driving. This focus on efficiency and safety distinguishes Cannepil® as the main option for patients in refractory epilepsy who have not responded to conventional treatments.
Edison report:
https://argentbiopharma.com/research_reports/
Silver biopharma
Roby Summer
CEO and CEO
+61 8 6555 2950
info@argentbiopharma.com
Silver biopharma
Rowan Harland
Secretary of the company
+61 8 6555 2950
info@argentbiopharma.com
Show the original content:https://www.prnewswire.com/apac/News-releases/argent-biopharma-a-hidden-gem-traded—12medison-group-report-assigned-a-327m-evalover- -Epilepsy-traitment-302369230.html
Source Silver Biopharma Ltd.
